US Stock Insider Trading | Twist Bioscience Disclosed Two Insider Trading Transactions on February 13

K-LinePoet · 2026-03-15T19:47:18+00:00

Twist Bioscience (TWST) disclosed multiple insider transactions on February 13, 2026, with executives and directors selling up to 16,000 shares in recent periods. The company is committed to serving multiple sectors through synthetic DNA tools to advance sustainable development.

K-LinePoet

2026-03-15 19:47:18

Abstract generation in progress

On February 13, 2026, Twist Bioscience (TWST) disclosed two insider trading transactions. Executive Laponis Adam sold 7,000 shares on February 12, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 13, 2026	Executive	Cho Dennis	February 11, 2026	Sell	5,000	49.93	$249,700
February 13, 2026	Executive	Laponis Adam	February 12, 2026	Sell	7,000	50.00	$350,000
February 9, 2026	Director	JOHANNESSEN JAN	February 6, 2026	Sell	2,200	47.91	$105,420
February 5, 2026	Executive	Finn Patrick John	February 3, 2026	Sell	2,705	46.58	$125,911
February 5, 2026	Executive	WERNER ROBERT F.	February 3, 2026	Sell	175	46.58	$8,150.80
February 5, 2026	Executive	WERNER ROBERT F.	February 4, 2026	Sell	7,000	45.65	$319,550
February 5, 2026	Executive	Green Paula	February 3, 2026	Sell	1,194	46.58	$55,560.52
February 5, 2026	Director	Leproust Emily M.	February 3, 2026	Sell	5,001	46.58	$232,900.58
February 5, 2026	Executive	Cho Dennis	February 3, 2026	Sell	1,099	46.58	$51,124.82
January 27, 2026	Executive	Finn Patrick John	January 23, 2026	Sell	2,390	44.91	$107,259.90

[Company Profile]

Twist Bioscience Corporation was incorporated on February 4, 2013, in Delaware. The company is dedicated to serving customers who are working to make the world a better place. In healthcare, food/agriculture, industrial chemicals, academic research, and data storage, customers are utilizing their synthetic DNA tools to develop ways to improve lives and enhance Earth’s sustainability. They have developed a disruptive DNA synthesis platform that enables the biological engineering industry to produce DNA for a wide range of applications and markets. They combine silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure, and e-commerce platforms to create an integrated technology platform.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes